Li Ooi M, et al. - In patients with recalcitrant chronic rhinosinusitis (CRS) due to Staphylococcus aureus, researchers studied the safety, tolerability, and preliminary effectiveness of ascending multiple intranasal doses of investigational phage cocktail AB-SA01. Participants in the study were patients with recalcitrant CRS, aged 18-70 years, in whom surgical and medical treatment had failed and who had positive S aureus cultures sensitive to AB-SA01. According to this phase 1, first-in-humans, open-label clinical trial of multiple ascending doses, safe and well tolerated 14-day intranasal irrigation with AB-SA01 doses to 3 × 10⁹ plaque-forming units with promising preliminary efficacy findings. Phage therapy for patients with CRS could be an alternative to antibiotics.